WO1999040106A3 - Use of angiotensin analogues for promoting erythropoiesis - Google Patents
Use of angiotensin analogues for promoting erythropoiesis Download PDFInfo
- Publication number
- WO1999040106A3 WO1999040106A3 PCT/US1999/002648 US9902648W WO9940106A3 WO 1999040106 A3 WO1999040106 A3 WO 1999040106A3 US 9902648 W US9902648 W US 9902648W WO 9940106 A3 WO9940106 A3 WO 9940106A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogues
- angiotensin
- aii
- fragments
- erythropoiesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/32—Angiotensins [AT], angiotensinogen
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002319701A CA2319701C (en) | 1998-02-09 | 1999-02-08 | Method of promoting erythropoiesis |
JP2000530534A JP2002509077A (en) | 1998-02-09 | 1999-02-08 | Erythropoiesis promotion method |
AU25916/99A AU2591699A (en) | 1998-02-09 | 1999-02-08 | Method of promoting erythropoiesis |
EP99905848A EP1053004A2 (en) | 1998-02-09 | 1999-02-08 | Use of angiotensin analogues for promoting erythropoiesis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7410698P | 1998-02-09 | 1998-02-09 | |
US11153598P | 1998-12-09 | 1998-12-09 | |
US60/111,535 | 1998-12-09 | ||
US60/074,106 | 1998-12-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999040106A2 WO1999040106A2 (en) | 1999-08-12 |
WO1999040106A3 true WO1999040106A3 (en) | 1999-09-23 |
Family
ID=26755261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/002648 WO1999040106A2 (en) | 1998-02-09 | 1999-02-08 | Use of angiotensin analogues for promoting erythropoiesis |
Country Status (6)
Country | Link |
---|---|
US (3) | US6239109B1 (en) |
EP (1) | EP1053004A2 (en) |
JP (1) | JP2002509077A (en) |
AU (1) | AU2591699A (en) |
CA (1) | CA2319701C (en) |
WO (1) | WO1999040106A2 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335195B1 (en) * | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
EP1053004A2 (en) * | 1998-02-09 | 2000-11-22 | University Of Southern California | Use of angiotensin analogues for promoting erythropoiesis |
US7173011B2 (en) * | 2000-11-20 | 2007-02-06 | University Of Southern California | Radiation therapy methods |
DE69924715T2 (en) * | 1998-05-11 | 2006-01-26 | University Of Southern California, Los Angeles | USE OF ANGIOTENSIN ANALOGUE FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING THE LIFE OF BLOOD CELLS AND MOBILIZING HAEMATOPOETIC STEM CELLS AFTER CHEMOTHERAPEUTIC TREATMENT |
US6916783B2 (en) * | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
CA2339330A1 (en) | 1998-08-13 | 2000-02-24 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
US6730775B1 (en) | 1999-03-23 | 2004-05-04 | University Of Southern California | Methods for limiting scar and adhesion formation |
US6821953B1 (en) | 1999-12-16 | 2004-11-23 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
WO2001078759A1 (en) * | 2000-04-13 | 2001-10-25 | National University Of Singapore | The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of glomerulosclerosis and renal failure |
US6747008B1 (en) | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
MXPA03011693A (en) | 2001-05-31 | 2004-12-06 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists. |
US7375073B2 (en) | 2002-02-27 | 2008-05-20 | Wake Forest University Health Sciences | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
US7273896B2 (en) * | 2003-04-10 | 2007-09-25 | Angiotech Pharmaceuticals (Us), Inc. | Compositions and methods of using a transient colorant |
US7588745B2 (en) * | 2004-04-13 | 2009-09-15 | Si Options, Llc | Silicon-containing products |
CA2648035A1 (en) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia |
EP2187943A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
WO2009040051A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
AU2008303909A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of Tyr-w-Mif-1 and urocortin 2 as therapeutic agents |
RU2010113981A (en) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | APPLICATION OF A HEXAPEPTIDE ANTAGONIST RECEPTOR OF THROMBOCITARY FIBRINOGEN AND ALPHA-ENDORPHINE AS A THERAPEUTIC |
CN103694337B (en) | 2008-02-08 | 2016-03-02 | Ambrx公司 | Modified leptin polypeptide and its purposes |
US20090227507A1 (en) * | 2008-03-10 | 2009-09-10 | University Of Southern California | Angiotensin (1-7) Dosage Forms and Uses Thereof |
EP3225248B1 (en) | 2008-07-23 | 2023-06-07 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
AU2009296397B2 (en) | 2008-09-26 | 2012-11-08 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
TWI480288B (en) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
ES2649905T3 (en) * | 2012-03-30 | 2018-01-16 | Daiichi Sankyo Company, Limited | Succinic (2-heteroarylamino) acid derivative |
US9688724B2 (en) | 2012-05-14 | 2017-06-27 | University Of Southern California | Methods for limiting development of a skin wound |
US8557958B1 (en) | 2012-06-18 | 2013-10-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of diabetes |
US8633158B1 (en) | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
US9623084B2 (en) | 2013-03-15 | 2017-04-18 | University Of Southern California | Methods for treating multiple sclerosis |
WO2014145331A1 (en) | 2013-03-15 | 2014-09-18 | University Of Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
JP6254692B2 (en) | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | Methods for treating cognitive dysfunction |
US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
WO2016014342A2 (en) | 2014-07-21 | 2016-01-28 | Arizona Board Of Regents For The University Of Arizona | Ang-(1-7) derviative oligopeptides and methods for using and producing the same |
US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
CA2998862A1 (en) | 2015-09-18 | 2017-03-23 | Wake Forest University Health Sciences | Angiotensin (1-7) analogs and methods relating thereto |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
EP4007592A1 (en) | 2019-08-02 | 2022-06-08 | LanthioPep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015629A (en) * | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
WO1995008337A1 (en) * | 1993-09-24 | 1995-03-30 | The University Of Southern California | Use of angiotensin iii and analogs thereof in tissue repair |
WO1996039164A1 (en) * | 1995-06-06 | 1996-12-12 | The University Of Southern California | Use of angiotensin ii type 2 receptor agonists in tissue repair |
WO1998032457A2 (en) * | 1997-01-28 | 1998-07-30 | University Of Southern California | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
WO1999026644A1 (en) * | 1997-11-26 | 1999-06-03 | University Of Southern California | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
WO1999031125A1 (en) * | 1997-12-12 | 1999-06-24 | University Of Southern California | Wound healing compositions |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR880012235A (en) | 1987-04-10 | 1988-11-26 | 벤자민 에프.람버트 | How to increase hematocrit in normal mammals |
US5032507A (en) | 1987-11-13 | 1991-07-16 | The Salk Institute For Biological Studies | Potentiation of erythropoiesis |
US4987121A (en) | 1988-05-27 | 1991-01-22 | Center For Innovative Technology | Erythropoietic factor |
WO1990008822A1 (en) * | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
IL89662A (en) | 1989-03-19 | 1997-11-20 | Interpharm Lab Ltd Kiryat Weiz | Pharmaceutical compositions comprising interferon-beta |
US5824297A (en) * | 1990-06-25 | 1998-10-20 | Oncogene Science, Inc. | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
US5188828A (en) | 1990-11-08 | 1993-02-23 | Brigham And Women's Hospital | Interleukin-6 to stimulate erythropoietin production |
US5482924A (en) | 1991-05-06 | 1996-01-09 | Centre National De La Recherche | Proteinaceous compositions having an activity on erythropoiesis |
US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US5955430A (en) | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
CA2172494A1 (en) * | 1993-09-24 | 1995-03-30 | Kathleen Elizabeth Rodgers | Use of angiotensin ii analogs in tissue repair |
US5610056A (en) * | 1994-11-16 | 1997-03-11 | Amgen Inc. | Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells |
WO1996039628A1 (en) * | 1995-06-06 | 1996-12-12 | Stemcell Therapeutics L.L.C. | GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS |
EP1053004A2 (en) * | 1998-02-09 | 2000-11-22 | University Of Southern California | Use of angiotensin analogues for promoting erythropoiesis |
DE69924715T2 (en) * | 1998-05-11 | 2006-01-26 | University Of Southern California, Los Angeles | USE OF ANGIOTENSIN ANALOGUE FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING THE LIFE OF BLOOD CELLS AND MOBILIZING HAEMATOPOETIC STEM CELLS AFTER CHEMOTHERAPEUTIC TREATMENT |
US6762167B1 (en) * | 1998-05-11 | 2004-07-13 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
US20040120959A1 (en) | 2001-01-08 | 2004-06-24 | Karl Tryggvason | Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis |
-
1999
- 1999-02-08 EP EP99905848A patent/EP1053004A2/en not_active Withdrawn
- 1999-02-08 US US09/245,680 patent/US6239109B1/en not_active Expired - Lifetime
- 1999-02-08 WO PCT/US1999/002648 patent/WO1999040106A2/en not_active Application Discontinuation
- 1999-02-08 JP JP2000530534A patent/JP2002509077A/en active Pending
- 1999-02-08 AU AU25916/99A patent/AU2591699A/en not_active Abandoned
- 1999-02-08 CA CA002319701A patent/CA2319701C/en not_active Expired - Fee Related
-
2000
- 2000-09-08 US US09/658,315 patent/US7288522B1/en not_active Expired - Fee Related
-
2007
- 2007-06-06 US US11/810,560 patent/US7745411B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015629A (en) * | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
WO1995008337A1 (en) * | 1993-09-24 | 1995-03-30 | The University Of Southern California | Use of angiotensin iii and analogs thereof in tissue repair |
WO1996039164A1 (en) * | 1995-06-06 | 1996-12-12 | The University Of Southern California | Use of angiotensin ii type 2 receptor agonists in tissue repair |
WO1998032457A2 (en) * | 1997-01-28 | 1998-07-30 | University Of Southern California | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
WO1999026644A1 (en) * | 1997-11-26 | 1999-06-03 | University Of Southern California | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
WO1999031125A1 (en) * | 1997-12-12 | 1999-06-24 | University Of Southern California | Wound healing compositions |
Non-Patent Citations (1)
Title |
---|
M MRUG ET AL.: "Angiotensin II stimulates proliferation of normal early erythroid progenitors", J. CLIN. INVEST., vol. 100, no. 9, 1 November 1997 (1997-11-01), pages 2310 - 2314, XP002077069 * |
Also Published As
Publication number | Publication date |
---|---|
US20090062210A1 (en) | 2009-03-05 |
EP1053004A2 (en) | 2000-11-22 |
WO1999040106A2 (en) | 1999-08-12 |
AU2591699A (en) | 1999-08-23 |
CA2319701C (en) | 2009-09-29 |
CA2319701A1 (en) | 1999-08-12 |
US7288522B1 (en) | 2007-10-30 |
US6239109B1 (en) | 2001-05-29 |
JP2002509077A (en) | 2002-03-26 |
US7745411B2 (en) | 2010-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999040106A3 (en) | Use of angiotensin analogues for promoting erythropoiesis | |
EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
CA2454584A1 (en) | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient | |
CA2322963A1 (en) | Methods to increase white blood cell survival after chemotherapy | |
EP1094829B8 (en) | Methods for accelerating bone and cartilage growth and repair | |
BR0016058A (en) | Phosphonate Compounds | |
IL125735A (en) | Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound | |
EP1024145A3 (en) | Novel azalides and methods of making same | |
EA200000298A1 (en) | Prostaglandin agonists and their application for the treatment of bone diseases | |
LU92425I2 (en) | Ra 2232 radium dichloride and its pharmaceutically acceptable derivatives (XOFIGO®) | |
WO1998058911A3 (en) | Prostaglandin agonists | |
BR0009651A (en) | Compound, process for preparing a compound, pharmaceutical composition, use of a compound, and method for treating rheumatoid arthritis and an obstructive airway disease | |
TW349021B (en) | Pharmaceutical compositions containing interleukin-12 for preventing graft versus host disease | |
UA66865C2 (en) | Indenopyrrolocarbazoles, pharmaceutical composition, method for inhibiting kinase activity and method for treatment (variants) | |
HRP20020330A2 (en) | Novel oligosaccharides, preparation method and pharmaceutical compositions containing same | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
WO2001042243A3 (en) | Protein kinase inhibitors | |
PT1223972E (en) | Suspension of an EPI-HNE Protein A process for preparing an aneroxylated derivative of the pharmaceutical composition comprising the aforesaid suspension or aerosol and its uses | |
ATE335496T1 (en) | ANGIOTENSIN II AND ANALOGUES FOR LIMITING SCARS AND ADHESION FORMATION | |
UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
WO2001043761A3 (en) | Methods for treating and preventing damage to mucosal tissue | |
WO2001055176A3 (en) | Methods for inhibiting smooth muscle cell proliferation | |
WO2005016371A8 (en) | IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES | |
WO1999050671A3 (en) | Toso as a target for drug screening | |
WO2002018363A3 (en) | 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/007509 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2319701 Country of ref document: CA Ref country code: CA Ref document number: 2319701 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 25916/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 530534 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999905848 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999905848 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999905848 Country of ref document: EP |